Zacks Investment Research upgraded shares of OPKO HEALTH INC (OPK) from NEUTRAL to OUTPERFORM on October 01, 2014, with a target price of $10.20.
eXegenics Inc. is biopharmaceutical company specializing in the development of therapeutic and diagnostic products for human diseases with an emphasis on the treatment and prevention of cancer and infectious diseases. Its research and development activities relate principally to its proprietary Paclitaxel production system using fermentation and genetic engineering in agreements with Bristol-Myers Squibb, the treatment of Polycystic Kidney Disease using paclitaxel, Quantum Core Technology, our proprietary rational drug design targeting the human genome.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on OPKO HEALTH INC (OPK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment